Cargando…
ICER releases pricing models for potential COVID-19 treatments
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228862/ https://www.ncbi.nlm.nih.gov/pubmed/32454583 http://dx.doi.org/10.1007/s40274-020-6796-3 |
Ejemplares similares
-
Worldwide HTA access to ICER's cost-effectiveness models
Publicado: (2020) -
Factors affecting COVID-19 vaccine acceptability in the US
Publicado: (2020) -
No evidence of adverse neurological outcomes from COVID-19 vaccines
Publicado: (2022) -
FDA limits authorised use of Janssen COVID-19 vaccine
Publicado: (2022) -
COVID-19 lockdown increased diabetic mortality, morbidity and costs in Italy
Publicado: (2021)